Michael Gilman, Arrakis CEO (via Obsidian)
Busy Amgen swings another deal, this time with RNA drugging player Arrakis for 'several billion'
Less than a week after inking a $1.9 billion collaboration with Flagship’s Generate to boost its AI capabilities, Amgen is returning to the dealmaking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
